Healthcare provider profile · identity verified

Timothy J. Pehl, MD

Family Practice · GRAND RAPIDS, MN · NPI 1194702779

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	649	176
Lisinopril	Lisinopril	440	127
Amlodipine Besylate	Amlodipine Besylate	349	111
Losartan Potassium	Losartan Potassium	311	92
Levothyroxine Sodium	Levothyroxine Sodium	292	70
Tamsulosin Hcl	Tamsulosin Hcl	279	80
Metoprolol Succinate	Metoprolol Succinate	249	80
Hydrochlorothiazide	Hydrochlorothiazide	230	70
Metformin Hcl	Metformin Hcl	218	63
Gabapentin	Gabapentin	171	47
Omeprazole	Omeprazole	166	41
Tramadol Hcl	Tramadol Hcl	150	27
Jardiance	Empagliflozin	136	32
Simvastatin	Simvastatin	136	39
Sertraline Hcl	Sertraline Hcl	132	37
Lorazepam	Lorazepam	122	33
Venlafaxine Hcl Er	Venlafaxine Hcl	122	16
Rosuvastatin Calcium	Rosuvastatin Calcium	115	38
Furosemide	Furosemide	98	35
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	93	25
Trazodone Hcl	Trazodone Hcl	90	28
Allopurinol	Allopurinol	85	23
Eliquis	Apixaban	82	15
Pravastatin Sodium	Pravastatin Sodium	76	25
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	73	suppressed
Metformin Hcl Er	Metformin Hcl	67	19
Meloxicam	Meloxicam	64	28
Chlorthalidone	Chlorthalidone	56	15
Pantoprazole Sodium	Pantoprazole Sodium	54	19
Metoprolol Tartrate	Metoprolol Tartrate	53	20
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	50	16
Finasteride	Finasteride	49	18
Aripiprazole	Aripiprazole	48	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	47	17
Spironolactone	Spironolactone	47	13
Glipizide	Glipizide	46	suppressed
Oxycodone Hcl	Oxycodone Hcl	46	13
Potassium Chloride	Potassium Chloride	45	12
Buspirone Hcl	Buspirone Hcl	44	suppressed
Duloxetine Hcl	Duloxetine Hcl	44	13
Bupropion Xl	Bupropion Hcl	43	19
Albuterol Sulfate Hfa	Albuterol Sulfate	42	21
Paroxetine Hcl	Paroxetine Hcl	42	suppressed
Brilinta	Ticagrelor	41	suppressed
Fluticasone Propionate	Fluticasone Propionate	39	16
Levetiracetam	Levetiracetam	39	suppressed
Montelukast Sodium	Montelukast Sodium	38	15
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	38	13
Carvedilol	Carvedilol	37	16
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	36	suppressed
Warfarin Sodium	Warfarin Sodium	36	suppressed
Jantoven	Warfarin Sodium	35	suppressed
Atenolol	Atenolol	34	14
Baclofen	Baclofen	34	suppressed
Famotidine	Famotidine	34	suppressed
Prednisone	Prednisone	34	19
Tizanidine Hcl	Tizanidine Hcl	34	suppressed
Xarelto	Rivaroxaban	32	11
Escitalopram Oxalate	Escitalopram Oxalate	30	suppressed
Glimepiride	Glimepiride	29	suppressed
Hydrocortisone	Hydrocortisone	29	suppressed
Spiriva Respimat	Tiotropium Bromide	29	suppressed
Ventolin Hfa	Albuterol Sulfate	28	14
Alendronate Sodium	Alendronate Sodium	26	suppressed
Humalog Kwikpen U-100	Insulin Lispro	26	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	26	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	26	suppressed
Trulicity	Dulaglutide	26	suppressed
Incruse Ellipta	Umeclidinium Bromide	25	suppressed
Nabumetone	Nabumetone	23	suppressed
Clopidogrel	Clopidogrel Bisulfate	22	suppressed
Ozempic	Semaglutide	22	suppressed
Citalopram Hbr	Citalopram Hydrobromide	21	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	21	suppressed
Januvia	Sitagliptin Phosphate	21	suppressed
Farxiga	Dapagliflozin Propanediol	20	suppressed
Glipizide Er	Glipizide	20	suppressed
Abrysvo	Rsv Vacc, Pref A And Pref B/Pf	19	19
Amitriptyline Hcl	Amitriptyline Hcl	19	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	19	suppressed
Clonidine Hcl	Clonidine Hcl	19	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	19	suppressed
Donepezil Hcl	Donepezil Hcl	19	suppressed
Shingrix	Varicella-Zoster Ge/As01b/Pf	19	15
Triamcinolone Acetonide	Triamcinolone Acetonide	19	15
Zolpidem Tartrate	Zolpidem Tartrate	19	suppressed
Ibuprofen	Ibuprofen	17	suppressed
Torsemide	Torsemide	17	suppressed
Azithromycin	Azithromycin	16	suppressed
Chlorhexidine Gluconate	Chlorhexidine Gluconate	16	suppressed
Indomethacin	Indomethacin	16	suppressed
Lamotrigine	Lamotrigine	16	suppressed
Symbicort	Budesonide/Formoterol Fumarate	16	suppressed
Varenicline Tartrate	Varenicline Tartrate	16	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	14	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	14	suppressed
Olanzapine	Olanzapine	14	suppressed
Bumetanide	Bumetanide	13	suppressed
Dantrolene Sodium	Dantrolene Sodium	13	suppressed
Digoxin	Digoxin	13	suppressed
Divalproex Sodium	Divalproex Sodium	13	suppressed
Methadone Hcl	Methadone Hcl	13	suppressed
Nitroglycerin	Nitroglycerin	13	12
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	13	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	13	suppressed
Atenolol-Chlorthalidone	Atenolol/Chlorthalidone	12	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	12	suppressed
Hydralazine Hcl	Hydralazine Hcl	12	suppressed
Propranolol Hcl Er	Propranolol Hcl	12	suppressed
Topiramate	Topiramate	12	suppressed
Arnuity Ellipta	Fluticasone Furoate	11	suppressed
Fiasp Flextouch	Insulin Aspart (Niacinamide)	11	suppressed
Lubiprostone	Lubiprostone	11	suppressed
Novolog Flexpen	Insulin Aspart	11	suppressed
Topiramate Er	Topiramate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error